Trials / Completed
CompletedNCT01238393
Treatment of Epiretinal Membranes With Ranibizumab
A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Queen's University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intravitreal ranibizumab | monthly injections x3 +/- 2nd series of 3 |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-11-01
- Completion
- 2012-01-01
- First posted
- 2010-11-10
- Last updated
- 2016-01-13
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01238393. Inclusion in this directory is not an endorsement.